Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Patients receiving acyclovir as standard of care will be enrolled into this study. The currently recommended dosing strategy at our institution for obese patients is to receive intravenous acyclovir dosed per an adjusted body weight \[IBW + 0.4(TBW-IBW)\]. They will have blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total time period of 12 hours. These patients will already be hospitalized for other reasons, and will not be required to make additional trips to the hospital. A total of approximately 4-5 tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control (non-obese) patients will be enrolled.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years of age

• Receiving intravenous acyclovir 5 mg/kg (TBW for normal weight patients and ABW40 for obese patients) as part of their routine care

• Weight \> 190% of ideal body weight (IBW) for obese patients or weight 80-120% of IBW for matched control patients.

Locations
United States
West Virginia
West Virginia University Hospitals
RECRUITING
Morgantown
Contact Information
Primary
Pam Bunner
bunnerp@wvumedicine.org
304-598-4511
Time Frame
Start Date: 2016-08
Estimated Completion Date: 2025-12
Participants
Target number of participants: 20
Treatments
Obese Patients
Obese patients (patients whose weight is \>190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
Non-obese Patients
Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
Related Therapeutic Areas
Sponsors
Leads: West Virginia University

This content was sourced from clinicaltrials.gov